January 15, 2020 — With public data set to play an increasingly important role in drug discovery and development, an integrated, data-driven approach to clinical planning can optimize the probability of success. The increasing availability of public data sets, such as The Cancer Genome Atlas (TCGA) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), offers a […]
This author has not written his bio yet.
But we are proud to say that raincastle contributed 56 entries already.
Entries by raincastle
November 13, 2019 — Quizartinib, a once-daily, oral, highly potent and selective FLT3 inhibitor, demonstrated a significant improvement in survival vs SC in FLT3-ITD-positive R/R AML in the global, randomized, phase 3 QuANTUM-R study (Cortes et al. Lancet Oncol, 2019; NCT02039726). Patients with R/R FLT3-ITD-positive AML were randomized 2:1 to receive single agent quizartinib or […]
November 8, 2019 — This article explores biomarker data trends and challenges, and shares how drug developers, translational scientists, and clinical researchers evaluating biomarkers in early-phase studies can reduce time and cost.
July 16, 2019 — Boston, MA — QuartzBio, part of Precision for Medicine, today announced a significant expansion of its computational biology and multiomic data integration capabilities through the launch of a Boston-based office. The new office is one of many recent investments in Artificial Intelligence and computational biology expertise to cement its position as […]
March 6, 2019 — Bethesda, MD — Precision for Medicine, part of Precision Medicine Group, today announced the acquisition of SimplicityBio, adding artificial intelligence to Precision’s QuartzBio™ multiomic data integration and informatics platform. The addition of an artificial intelligence engine to QuartzBio provides Precision’s clients the most robust, sophisticated end-to-end solution for the “big data” challenge observed in […]
March 4, 2019 — Since the turn of the century, the use of biomarkers in drug discovery and development has exploded at an unprecedented rate. Recent scientific and technologic breakthroughs allow biomarkers to be leveraged to address many questions about biological activity, safety, and clinical efficacy throughout the drug discovery and development process—at a fraction […]
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO logo® are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved. The names and logos of other companies and products appearing on the website may be trademarks or registered trademarks of such other companies.